Abstract
Gelatinous marrow transformation (GMT) is characterized by accumulation of extracellular
gelatinous substances such as mucopolysaccharides, fat cell atrophy, and focal loss
of hematopoietic cells. It is a rare disorder of unknown pathogenesis. Anorexia nervosa,
acute febrile state, acquired immunodeficiency syndrome, heart failure, lymphomas,
and carcinomas are some of the entities associated with GMT. A 57-year-old male patient
presented with abdominal distension of 1-month duration. He was diagnosed as chronic
myeloid leukemia (CML) and treated with imatinib. Repeat testing 2 years later revealed
a normal hemogram. However, in view of his BCR::ABL1 levels of 17%, he was switched to dasatinib. Patient presented with fever, fatigue,
and reduced appetite 4 months later. Hemogram revealed pancytopenia. Bone marrow examination
showed a hypocellular marrow with trilineage suppression and gelatinous transformation.
GMT in CML patients' posttherapy is a rare encounter. It is essential to identify
this clinical scenario for optimal patient management and monitoring progression of
disease.
Keywords
dasatinib - gelatinous marrow transformation - chronic myeloid leukemia - case report
